Therapeutic Pipeline
Program Description and Application Process
The IDDP Program aims to promote for-profit interest in JDRF’s mission to find a cure for type 1 diabetes and its complications. JDRF IDDP funding is available to support research programs in companies or for-profit entities worldwide, either publicly or privately held, focused on a priority area within JDRF’s mission (see JDRF’s most recent Research Emphasis Areas.)
The IDDP Program provides a mechanism and opportunity for JDRF to foster long-term collaborative relationships with industry, and to take promising Type 1 diabetes research through discovery and development and toward commercialization.
Completed Partnerships
AGTC & Genzyme Corporation: Study of anti-neovascular genes for treatment of diabetic retinopathy
Athersys, Inc.: Genome-Wide discovery of pancreatic islet cell differentiation factors using MAPC adult stem cells
Axxam: SpA Identification of Kv1.3 blockers for the treatment of type 1 diabetes
Bayhill Therapeutics: Phase I/II clinical trial of an antigen-specific immunotherapeutic DNA vaccine for type 1 diabetes
Biogen Idec: Investigation of novel pathways to promote beta cell regeneration
CoMentis, Inc.: Proof of concept testing of GTS-21, a selective ±7-nAChR agonist, to prevent or delay the onset of type 1 diabetes in NOD mice
CoMentis, Inc.: Proof of concept testing of mecamylamine as topical anti-angiogenic therapy in patients with diabetic macular edema
CyThera, Inc: Derivation, characterization, and distribution of embryonic stem cell lines
DeveloGen AG: Discovery and development of beta cell regeneration drugs for type 1 diabetes
EpiVax, Inc.: T1D Tolerance Induction with Natural Treg Epitopes
ES Cell International Pte Ltd: Isolation of clinically-compliant human embryonic stem cells
Genzyme Corporation: Development Partnership for Type 1 Diabetes Therapeutics Development
Immunocore Ltd.: A novel monoclonal T cell receptor (mTCR) therapeutic targeted towards a proprietary antigen associated with type I diabetes
MacroGenics, Inc.: A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of MGA031, a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus
Novocell, Inc: Encapsulated human islet allografts for the treatment of diabetes
Osiris Therapeutics, Inc.: Prochymal” for the treatment of patients with new onset type 1 diabetes mellitus
Plureon Corporation: Generation of pancreatic beta cells from pluripotent adult stem cells in human adipose tissue
Sangamo BioSciences, Inc.: A phase II clinical trial of SB-509, a novel VEGF – activator, in patients with diabetic neuropathy – development of novel clinical endpoints linked to efficacy and reversal of neuropathy
SmartCells, Inc.: Proof-of-concept for an injectable, glucose-regulated insulin for type 1 diabetes
Stemnion LLC: Differentiation of amnion-derived cells to clinically viable islets for transplantation
Tolerx, Inc.: Human clinical trials of TRX4, an anti-CD3 monoclonal antibody, in patients with Type 1 diabetes
Transition Therapeutics: Stimulation of Islet Cell Regeneration in Type 1 Diabetes with GLP-1 and Gastrin
Ximerex, Inc: Islet Transplantation into Non-Human Primates Using Chimeric Donor Pigs